FDA clarifies that no drugs are approved to treat COVID-19 after Trump names 2 contenders


President Trump held up two drugs as possible treatments for COVID-19, the disease caused by the new coronavirus, in a conference call with governors on Thursday. He said chloroquine, an older drug used to treat malaria, lupus, and rheumatoid arthritis, was "very powerful" and has shown "very, very encouraging early results," adding that the Food and Drug Administration has approved the drug for use against the coronavirus.
The FDA said in a subsequent statement that "there are no FDA-approved therapeutics or drugs to treat, cure, or prevent COVID-19." Doctors can prescribe chloroquine "off-label," for unapproved uses, to treat COVID-19 patients.
Chloroquine, which can be lethal if taken by children or in large doses, will be tested in a "large, pragmatic clinical trial" with coronavirus patients, FDA Commissioner Stephen Hahn told reporters after Trump's briefing. German pharmaceutical giant Beyer said Thursday it is donating 3 million tablets of its chloroquine phosphate drug, Resochin, to the U.S. government for COVID-19 treatment research. Resochin is not currently approved for use in the U.S. Rising Pharmaceuticals, the only U.S. manufacturer of chloroquine, nearly doubled the drug's price on Jan. 23 — then restored the original price after an outcry, calling the price hike "coincidental," the Financial Times reports.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Dr. Ross McKinney Jr., chief scientific officer for the Association of American Medical Colleges, told reporters Thursday that while chloroquine may look promising in test tubes, he's "skeptical it will be effective" in COVID-19 patients. Infectious disease experts are more optimistic about the other treatment Trump mentioned, the experimental antiviral drug remdesivir from Gilead Sciences. Remdesivir is being tested in at least five experiments.
Researchers are also experimenting with HIV medications, several treatments for rheumatoid arthritis, and the Japanese flu medicine favipiravir, The Associated Press reports. "We're looking at drugs that are already approved for other indications" as stopgap treatments, Hahn said, but "we want to make sure this is done well and right."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
An introvert's dream? Flu camps that offer £4,400 to spend two weeks alone
Under The Radar A fortnight in isolation may not be as blissful as it sounds
-
Can Trump put his tariffs on stronger legal footing?
Today's Big Question Appeals court says 'emergency' tariffs are improper
-
Film reviews: The Roses, Splitsville, and Twinless
Feature A happy union devolves into domestic warfare, a couple's open marriage reaps chaos, and an unlikely friendship takes surprising turns
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year